EA201500752A1 - Способ лечения заболеваний - Google Patents

Способ лечения заболеваний

Info

Publication number
EA201500752A1
EA201500752A1 EA201500752A EA201500752A EA201500752A1 EA 201500752 A1 EA201500752 A1 EA 201500752A1 EA 201500752 A EA201500752 A EA 201500752A EA 201500752 A EA201500752 A EA 201500752A EA 201500752 A1 EA201500752 A1 EA 201500752A1
Authority
EA
Eurasian Patent Office
Prior art keywords
animal
diseases
treatment
danazol
compound
Prior art date
Application number
EA201500752A
Other languages
English (en)
Inventor
Давид Бар-Ор
Original Assignee
Ампио Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ампио Фармасьютикалс, Инк. filed Critical Ампио Фармасьютикалс, Инк.
Publication of EA201500752A1 publication Critical patent/EA201500752A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4872—Body fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

В изобретении предложен способ ингибирования сверхпроницаемости сосудов у нуждающегося в этом животного. Способ содержит введение животному соединения даназола в количестве, ингибирующем сверхпроницаемость сосудов. Способ содержит введение животному эффективного количества соединения даназола в соответствии с содержанием жира в организме животного. В изобретении также предложен способ модулирования цитоскелета эндотелиальных клеток у животного.
EA201500752A 2012-12-19 2013-12-19 Способ лечения заболеваний EA201500752A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739524P 2012-12-19 2012-12-19
PCT/US2013/076421 WO2014100352A1 (en) 2012-12-19 2013-12-19 Method for treatment of diseases

Publications (1)

Publication Number Publication Date
EA201500752A1 true EA201500752A1 (ru) 2016-05-31

Family

ID=50979197

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500752A EA201500752A1 (ru) 2012-12-19 2013-12-19 Способ лечения заболеваний

Country Status (15)

Country Link
US (2) US9351979B2 (ru)
EP (1) EP2934546A4 (ru)
JP (1) JP2016503794A (ru)
KR (1) KR20150105355A (ru)
CN (1) CN104968350A (ru)
AU (1) AU2013361338A1 (ru)
BR (1) BR112015014261A8 (ru)
CA (1) CA2895340A1 (ru)
EA (1) EA201500752A1 (ru)
HK (1) HK1216504A1 (ru)
IL (1) IL239273A0 (ru)
MX (1) MX2015007845A (ru)
PH (1) PH12015501561A1 (ru)
SG (2) SG10201705044YA (ru)
WO (1) WO2014100352A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202010017530U1 (de) 2009-06-22 2012-03-28 Dmi Acquisition Corp. Danazolverbindung zur Behandlung von Krankheiten
US9532866B2 (en) * 2012-03-15 2017-01-03 L&C Bio Co., Ltd. Acellular dermal graft
SG10201705044YA (en) * 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
SG11201903254PA (en) * 2016-10-17 2019-05-30 Univ Keio Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
AU2018380300B2 (en) * 2017-12-08 2022-06-16 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL104564C (ru) 1958-07-23
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
GB1123770A (en) 1966-11-15 1968-08-14 Sterling Drug Inc 2-cyano-3-oxo-steroids
US4160027A (en) 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5714481A (en) 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4837212A (en) 1984-11-15 1989-06-06 University Of Miami Treatment of hemolytic anemia with danazol
US4975537A (en) 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
AU604236B2 (en) 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
DE3738620A1 (de) 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
US5407926A (en) 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
JP2680614B2 (ja) 1988-08-01 1997-11-19 日清製粉株式会社 ダナゾール組成物
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5372996A (en) 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
EP0485392B1 (en) 1989-07-07 1998-09-09 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
AU657690B2 (en) 1990-06-11 1995-03-23 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JPH04149132A (ja) 1990-10-13 1992-05-22 Bairon Boeki Kk ダナゾール水溶液
JPH0735335B2 (ja) 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
JP3328729B2 (ja) 1991-06-18 2002-09-30 ラボラトアール、テラメックス、エス、ア 抗緑内障薬剤組成物
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
EP1236470A3 (en) 1991-11-22 2004-09-01 Alcon Laboratories, Inc. Angiostatic steroids
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
DE69326836T2 (de) 1992-04-21 2000-02-24 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
ES2068742B1 (es) 1993-02-11 1995-11-16 Uriach & Cia Sa J Nuevos derivados de piridinio.
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
JPH09511507A (ja) 1994-04-04 1997-11-18 フリーマン，ウイリアム・アール 上昇した眼圧を治療するためのホスホニルメトキシアルキルヌクレオシドの使用
US5885591A (en) 1996-07-02 1999-03-23 Johnson & Johnson Consumer Products, Inc. Personal lubricant compositions
US5929111A (en) 1996-12-18 1999-07-27 Alcon Laboratories, Inc. A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
WO1998043647A1 (en) 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
US6011023A (en) 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP0939124A3 (en) 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
US6645954B2 (en) 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
GB9807809D0 (en) 1998-04-09 1998-06-10 Multimed Ltd Compositions comprising ethisterone or its derivatives
JP2002520287A (ja) 1998-07-10 2002-07-09 ザ・ユニバーシティ・オブ・シドニー 黄斑変性における血管新生の予防的治療
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
EP1022027A1 (en) 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
DE69903278D1 (de) 1999-07-09 2002-11-07 Inst Pasteur De Lille Lille Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
ES2231257T3 (es) 1999-10-21 2005-05-16 Alcon Inc. Dispositivo para la administracion de farmacos.
EP1225879A2 (en) 1999-10-22 2002-07-31 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6562369B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
AU2001230864A1 (en) 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
GB2345851B (en) 2000-01-18 2004-05-26 Gavin Paul Vinson A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
AU785285B2 (en) 2000-03-10 2006-12-21 Sun Pharma Global Fze Methods and compositions for treating and preventing posterior segment ophthalmic disorders
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US20040082557A1 (en) 2001-01-26 2004-04-29 Wajszczuk Charles Paul Methods for treating estrogen-dependent disorders
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
WO2002087543A1 (en) 2001-05-01 2002-11-07 Biozone Laboratories, Inc. Sustained release formulations for nifedipine, dextromethorphan, and danazol
AU2002344237B8 (en) 2001-05-29 2008-11-06 Sirna Therapeutics, Inc. Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US20030050291A1 (en) 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors
US20030232798A1 (en) 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
WO2003013609A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
AU2003226349B2 (en) 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004054557A2 (en) 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CN1753683B (zh) 2002-12-20 2010-05-26 视可舒研究公司 预防和治疗不良眼部病症的眼用制剂
WO2004060322A2 (en) 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
CN100342856C (zh) 2003-04-10 2007-10-17 上海医药工业研究院 达那唑半固体骨架制剂的组合物
GB2400554B (en) 2003-04-16 2007-04-18 George Margetts Treatment of angiotensin II-induced cardiovascular disease
WO2004103406A1 (ja) 2003-05-26 2004-12-02 Japan Science And Technology Agency 血小板の減少または増加を伴う疾患の治療用組成物
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005053660A2 (en) 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20050143362A1 (en) 2003-12-31 2005-06-30 Mclane Michael W. Danazol for treatment of hypogonadism in the adult male
US7442681B2 (en) 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
EP1720573A4 (en) 2004-02-27 2008-04-02 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13
CA2560416A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
GB2420281A (en) 2004-11-22 2006-05-24 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of dermatological conditions
GB2421183A (en) 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
AU2006218654A1 (en) 2005-03-02 2006-09-08 Nascent Pharmaceutical. Inc. Combination therapy for topical application
PT1919290E (pt) * 2005-07-12 2014-03-20 Ampio Pharmaceuticals Inc Métodos e produtos para tratamento de doenças
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070173538A1 (en) 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20100330148A1 (en) 2006-03-20 2010-12-30 The Johns Hopkins University Mehods and compositions for inhibiting impdh-1 isoform 1
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
CN101024082A (zh) 2007-04-06 2007-08-29 张士东 一种全面预防和治疗心脑血管疾病复方药及其应用
ES2493641T3 (es) 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20110142914A1 (en) 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
EP2300011A4 (en) * 2008-05-27 2012-06-20 Dmi Life Sciences Inc METHODS AND THERAPEUTIC COMPOUNDS
DE202010017530U1 (de) * 2009-06-22 2012-03-28 Dmi Acquisition Corp. Danazolverbindung zur Behandlung von Krankheiten
WO2010151531A1 (en) 2009-06-22 2010-12-29 Dmi Acquistion Corp. Methods and products for treatment of diseases
EP2763678A1 (en) 2011-10-07 2014-08-13 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
SG10201705044YA (en) * 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases

Also Published As

Publication number Publication date
SG10201705044YA (en) 2017-07-28
IL239273A0 (en) 2015-07-30
US20140227347A1 (en) 2014-08-14
EP2934546A1 (en) 2015-10-28
MX2015007845A (es) 2015-09-29
BR112015014261A8 (pt) 2019-10-08
CA2895340A1 (en) 2014-06-26
PH12015501561A1 (en) 2015-09-21
WO2014100352A1 (en) 2014-06-26
US20160256475A1 (en) 2016-09-08
AU2013361338A1 (en) 2015-08-06
BR112015014261A2 (pt) 2017-07-11
US9351979B2 (en) 2016-05-31
KR20150105355A (ko) 2015-09-16
JP2016503794A (ja) 2016-02-08
EP2934546A4 (en) 2016-06-22
CN104968350A (zh) 2015-10-07
HK1216504A1 (zh) 2016-11-18
US10058562B2 (en) 2018-08-28
SG11201504380SA (en) 2015-07-30

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201390347A1 (ru) Лечение заболеваний
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112014017799A8 (pt) Compostos inibidores de metaloenzima
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
ECSP14030779A (es) Inhibidores del nampt
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
MY160127A (en) Method for treatment of diseases
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201201296A1 (ru) Способы лечения диабетических язв стопы
EA201491500A1 (ru) Способы лечения фиброза
EA201500752A1 (ru) Способ лечения заболеваний
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12016501784B1 (en) Glyt1 inhibitors for use in the treatment of hematological disorders
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
EA201490638A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2015007862A (es) Derivado de amida del acido cinamico.